Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
申请人:——
公开号:US20020045747A1
公开(公告)日:2002-04-18
Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
1-Phenyl-2-aza-3-trimethylsilyloxy-1,3-butadiene reacts with aliphatic, aromatic and cyclic ketones to give in good to excellent yields 6,6-disubstituted-1,3-perhydro-oxazin-4-ones which, in turn, have been readily converted into β-hydroxy carboxylic acids.
BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
申请人:Knopp Biosciences LLC
公开号:US20160075663A1
公开(公告)日:2016-03-17
Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
[EN] ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS<br/>[FR] DÉRIVÉS D'ALCOOL UTILISÉS EN TANT QU'AGENTS D'OUVERTURE DU CANAL POTASSIQUE KV7
申请人:H LUNDBECK AS
公开号:WO2019161877A1
公开(公告)日:2019-08-29
The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS
申请人:H. Lundbeck A/S
公开号:US20190256456A1
公开(公告)日:2019-08-22
The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.